Profile data is unavailable for this security.
About the company
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
- Revenue in USD (TTM)10.00k
- Net income in USD-37.28m
- Incorporated2003
- Employees35.00
- LocationGlycoMimetics Inc9708 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (240) 243-1201
- Fax+1 (240) 243-1018
- Websitehttps://glycomimetics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 15.92m | 12.00 | -- | 0.448 | 6.85 | 0.9951 | -14.38 | -14.38 | 10.88 | 11.96 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Sensei Biotherapeutics Inc | 0.00 | -31.92m | 16.01m | 27.00 | -- | 0.2737 | -- | -- | -1.20 | -1.20 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -36.55 | -47.03 | -39.39 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 16.07m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
Evaxion Biotech A/S - ADR | 124.00k | -14.69m | 16.17m | 49.00 | -- | -- | -- | 130.38 | -56.83 | -56.83 | 0.0902 | -- | -- | -- | -- | 2,530.61 | -- | -100.11 | -- | -131.65 | -- | -- | -11,846.77 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
Talis Biomedical Corp | 989.00k | -57.21m | 16.24m | 99.00 | -- | 0.2864 | -- | 16.42 | -31.44 | -31.44 | 0.5434 | 31.11 | 0.0092 | -- | 14.87 | 9,989.90 | -53.08 | -68.18 | -58.71 | -74.22 | 97.27 | -- | -5,784.73 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
Monopar Therapeutics Inc | 0.00 | -7.61m | 16.44m | 10.00 | -- | 2.20 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
KALA BIO Inc | 0.00 | -39.55m | 16.79m | 43.00 | -- | 2.52 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
GlycoMimetics Inc | 10.00k | -37.28m | 16.95m | 35.00 | -- | 0.5863 | -- | 1,695.41 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
VBI Vaccines Inc | 9.41m | -83.99m | 17.07m | 131.00 | -- | -- | -- | 1.81 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
Microbot Medical Inc | 0.00 | -10.26m | 17.24m | 22.00 | -- | 2.52 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
Neurosense Therapeutics Ltd | 0.00 | -11.28m | 17.50m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
Lyra Therapeutics Inc | 1.68m | -68.88m | 18.00m | 109.00 | -- | 0.2322 | -- | 10.71 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
Talphera Inc | 651.00k | -14.31m | 18.01m | 15.00 | -- | 1.10 | -- | 27.67 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 9.54m | 14.81% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 8.59m | 13.32% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 3.00m | 4.65% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.75m | 4.26% |
AXA Investment Managers UK Ltd.as of 31 Mar 2024 | 1.59m | 2.46% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.11m | 1.73% |
Millennium Management LLCas of 31 Mar 2024 | 746.95k | 1.16% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 715.89k | 1.11% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 510.91k | 0.79% |
Geode Capital Management LLCas of 31 Mar 2024 | 505.15k | 0.78% |